Scisparc Ltd (SPRC) Stock Analysis

Scisparc Ltd (SPRC) is a publicly traded company in the HEALTHCARE sector. It trades at $8.73, carries a market capitalization of $5.25M, a price-to-earnings ratio of 0.09. This page summarizes the public market data, fundamentals, and frequently asked questions for SPRC, with GNG Research's proprietary safety, quality, and valuation analysis available to members.

Sector: HEALTHCARE - BIOTECHNOLOGY

Exchange: NASDAQ

Key Metrics

Market Sentiment

Scisparc Ltd currently has a Bullish sentiment score of 0.49.

About Scisparc Ltd

Scisparc Ltd. is an innovative clinical-stage pharmaceutical company based in Tel Aviv, Israel, focused on the research and development of cannabinoid-based therapies. With a commitment to advancing medical science, Scisparc is dedicated to creating novel treatments that leverage the therapeutic potential of cannabinoids to address a variety of medical conditions. The company aims to improve patient outcomes through its cutting-edge drug development programs, positioning itself at the forefro...

GNG Research Analysis

GNG Research scores Scisparc Ltd (SPRC) on three proprietary dimensions — a Safety score, a Quality score, and a Valuation score — alongside fair value estimates and buy-price targets for 5,000+ companies. These ratings are reserved for members. Read how the scores are calculated on our methodology page, or see GNG Research plans to unlock the full rating for SPRC.

Frequently Asked Questions

Does SPRC pay dividends?

Scisparc Ltd (SPRC) does not currently pay a regular dividend.

What is SPRC's P/E ratio?

Scisparc Ltd has a price-to-earnings (P/E) ratio of 0.09.

What is SPRC's market cap?

Scisparc Ltd (SPRC) has a market capitalization of $5.25M with a current stock price of $8.73.